Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled Trial
Effects of Physical Exercise on Anxiety and Co-morbid Emotional Disturbances: A Clinical Trail in a Day Care Unit
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Nesttun
-
Bergen, Nesttun, Norway, 5221
- Solli Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent obtained
- Clinical diagnosis of panic disorder with and without agoraphobia according to The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR, 4th ed., text revision; American Psychiatric Association, 2000), established through administration of Structural Clinical Interview for DSM-IV axis I disorders (SCID I; First, Spitzer, Gibbon, & Williams, 1995).
Exclusion Criteria:
- Brain-organic disorders according to DSM-IV-TR
- The presence of psychotic disorders according to DSM-IV-TR, established through administration of SCID I
- Present substance-abuse
- Medical condition that excludes participation in physical activity
- Major Depressive Disorder according to DSM-IV-TR established through administration of SCID I.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Physical exercise
Manualised Exercise performed in groups (5-8 participants per group).
3 sessions (á 60 minutes) per week for 12 consecutive weeks
|
Manualised Exercise performed in groups (5-8 participants per group).
3 sessions (á 60 minutes) per week for 12 consecutive weeks
|
|
Active Comparator: Cognitive-behavioral therapy
Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
|
Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mobility Inventory (MI) - Alone & Accompanied
Time Frame: Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
|
Agoraphobic Cognitions Questionnaire (ACQ)
Time Frame: Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
|
Body Sensations Questionnaire
Time Frame: Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
|
Panic frequency - Self-report & Clinician-rating
Time Frame: Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
|
Panic distress/disability - Self-report & Clinician-rating
Time Frame: Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Beck Anxiety Inventory (BAI)
Time Frame: Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
|
State-Trait Anxiety Inventory - State & Trait (STAI S/T)
Time Frame: Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
|
Beck Depression Inventory II (BDI-II)
Time Frame: Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
|
Quality of Life Inventory (QoLI)
Time Frame: Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
Baseline; Pre-treatment; Post-treatment; 6-months follow-up; 12-monthts follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Anders Hovland, PsyD, University of Bergen
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 3.2007.499 (REK)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.